(0.35%) 5 079.75 points
(0.23%) 38 079 points
(0.48%) 17 744 points
(0.12%) $82.79
(2.80%) $1.760
(0.13%) $2 391.60
(0.44%) $28.53
(-0.58%) $948.70
(-0.12%) $0.936
(-0.28%) $10.96
(-0.17%) $0.801
(0.19%) $94.24
@ NOK0.159
Issued: 17 Apr 2024 @ 09:00
Return: 1.76%
Previous signal: Apr 17 - 07:54
Previous signal:
Return: -0.99 %
Live Chart Being Loaded With Signals
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases...
Stats | |
---|---|
Today's Volume | 19.22M |
Average Volume | 45.72M |
Market Cap | 436.11M |
EPS | NOK0 ( 2024-02-15 ) |
Next earnings date | ( NOK-0.0200 ) 2024-05-23 |
Last Dividend | NOK0 ( N/A ) |
Next Dividend | NOK0 ( N/A ) |
P/E | -0.290 |
ATR14 | NOK0.0100 (6.24%) |
Volume Correlation
BerGenBio ASA Correlation
10 Most Positive Correlations | |
---|---|
PLT.OL | 0.937 |
ELIMP.OL | 0.935 |
KMCP.OL | 0.931 |
TRVX.OL | 0.925 |
ELABS.OL | 0.908 |
ABG.OL | 0.895 |
AKER.OL | 0.893 |
VOW.OL | 0.892 |
SADG.OL | 0.891 |
EFUEL.OL | 0.884 |
10 Most Negative Correlations | |
---|---|
AYFIE.OL | -0.95 |
ATEA.OL | -0.929 |
TECH.OL | -0.886 |
ELK.OL | -0.885 |
BAKKA.OL | -0.882 |
BWO.OL | -0.877 |
PEXIP.OL | -0.871 |
BOUV.OL | -0.865 |
GOD.OL | -0.864 |
SMOP.OL | -0.862 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BerGenBio ASA Correlation - Currency/Commodity
BerGenBio ASA Financials
Annual | 2022 |
Revenue: | NOK389 000 |
Gross Profit: | NOK389 000 (100.00 %) |
EPS: | NOK-0.390 |
Q3 | 2023 |
Revenue: | NOK0 |
Gross Profit: | NOK-109 000 (0.00 %) |
EPS: | NOK-0.0107 |
Q2 | 2023 |
Revenue: | NOK0 |
Gross Profit: | NOK-7 000.00 (0.00 %) |
EPS: | NOK-0.150 |
Q1 | 2023 |
Revenue: | NOK0 |
Gross Profit: | NOK-7 000.00 (0.00 %) |
EPS: | NOK-0.0926 |
Financial Reports:
No articles found.
BerGenBio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators